Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00713193 · ClinicalTrials.gov registry record · Phase 3
Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)
A Phase 3 study of Thrombotic Thrombocytopenic Purpura, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00713193 is a Phase 3 study of Thrombotic Thrombocytopenic Purpura that has completed, run by Ohio State University. The registered enrollment target is 26 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00713193, a Phase 3 study of Thrombotic Thrombocytopenic Purpura, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This research involves the use of immune base therapy as an adjunct to plasma exchange, the present standard of care for thrombotic thrombocytopenic purpura (TTP). Funding source -FDA OOPD
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Cyclosporine
Study Locations (1)
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-11 |
| Est. Completion | 2017-09-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00713193
The ClinicalTrials.gov registry entry for NCT00713193 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thrombotic Thrombocytopenic Purpura appearing as the primary indexed condition, and to 2 interventions - of which Prednisone is the first listed.
NCT00713193 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00713193 about?
NCT00713193 is a clinical study titled "Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)". This research involves the use of immune base therapy as an adjunct to plasma exchange, the present standard of care for thrombotic thrombocytopenic purpura (TTP). Funding source -FDA OOPD
What is the current status of trial NCT00713193?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2007-11. Estimated completion is 2017-09-20.
What conditions does trial NCT00713193 study?
This clinical trial studies the following conditions: Thrombotic Thrombocytopenic Purpura.
What interventions are being tested in trial NCT00713193?
The interventions under investigation include: Prednisone (DRUG), Cyclosporine (DRUG).
Who is sponsoring clinical trial NCT00713193?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00713193 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombotic Thrombocytopenic Purpura
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.